#Italy #Florence #Sinocare #Menarini Diagnostics #CGM System

A. Menarini Diagnostics and Sinocare Exclusive Distribution Agreement

In a recent announcement, A. Menarini Diagnostics revealed a pivotal partnership with Sinocare for the exclusive distribution of a new Continuous Glucose Monitoring (CGM) system in Europe. This collaboration is poised to revolutionize diabetes management across more than 20 countries on the continent, enhancing the accessibility of advanced healthcare technologies.

The innovative Sinocare CGM system, now in its third generation, boasts the capability for precise and continuous blood sugar monitoring—an essential tool for millions living with diabetes. This partnership marks a significant milestone for both organizations, establishing A. Menarini as the sole distributor of this advanced healthcare technology in key European markets.

Dr. Jiangfeng Fei, the head of the CGM Business Unit at Sinocare, emphasized that this agreement not only highlights the commitment to making cutting-edge healthcare solutions widely available but also represents a strategic collaboration with a leader in the healthcare sector. “We are excited to partner with A. Menarini Diagnostics, which has a strong market presence and expertise in delivering healthcare innovations,” he stated.

With over 45 years of experience in promoting innovative healthcare solutions, A. Menarini Diagnostics is dedicated to improving patient outcomes through high-quality diagnostic tools. Fabio Piazzalunga, the General Manager and Global Head of the company, expressed optimism about the potential impact of this partnership. He remarked that securing exclusive rights for marketing and distributing the Sinocare CGM system aligns perfectly with their mission to provide refined health solutions. “We are confident that this alliance will meet the growing demand for advanced diabetes care solutions,” he said.

This collaboration leverages A. Menarini’s expansive network, expertise, and resources to ensure that the third generation of CGM systems reaches those who will benefit most from its advanced features. The expanded availability of Sinocare’s technology is expected to significantly improve diabetes management for patients across Europe.

About A. Menarini Diagnostics

A. Menarini Diagnostics stands out as a leader in the healthcare sector, with a history steeped in delivering innovative solutions aimed at enhancing health outcomes. For over four decades, the company has been committed to equipping healthcare professionals with the tools necessary to make safe and effective diagnoses, ultimately improving the quality of life for patients worldwide. As part of the Menarini Pharmaceutical Group, founded in 1886, A. Menarini Diagnostics currently operates in 140 countries, employing over 17,000 individuals and achieving a revenue of 4.375 billion euros in 2023.

About Sinocare

Founded in 2002, Sinocare has emerged as the largest manufacturer of blood glucose meters in Asia. The company was notable for being the first blood glucose meter firm to be publicly listed in China. With a vast commercial network across Asia, Europe, and North America, Sinocare has expanded through strategic partnerships and acquisitions, establishing itself as a leader in the point-of-care testing (POCT) market with a commitment to biosensor innovation.

The future looks promising as A. Menarini Diagnostics and Sinocare forge ahead together in changing the landscape of diabetes care. This strategic partnership signifies a shared vision of accessible and advanced healthcare solutions for diabetes patients across Europe, ultimately paving the way for enhanced quality of life.